Real‐World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth: A Large Retrospective Cohort Study
Authors' conclusion
Findings suggest semaglutide treatment via telehealth can achieve trial-level weight loss with similar safety profiles, supporting telehealth as an evidence-based approach to medical weight management.
Study context
- Population
- Patients with overweight and obesity who initiated semaglutide via telehealth between December 1, 2022, and June 1, 2023, with follow-up weight within ±14 days of week 68445 female, 210 male
- Participants
- 655 patients
- Outcome
- Body weight reduction
- Follow-up
- Week 68
Methodological detailstelehealth, deidentified EHRs, random sample
- Telehealth
- Deidentified EHRs
- Random sample
Main finding
As reported in the abstract
week 68 (±14 days)
Mean body weight reduction
−16.6%
SD 7.5%; 95% CI −17.1% to −16.0%
Observational data: associations, not effects.
Further findings
| Outcome | Estimate | P value |
|---|---|---|
| Predictors of categorical weight loss: female sex · week 68Female vs Male | OR (≥ 5% weight loss) 4.26 | P < 0.001 |
| Predictors of categorical weight loss: female sex · week 68Female vs Male | OR (≥ 10% weight loss) 5.90 | P < 0.001 |
| Predictors of categorical weight loss: female sex · week 68Female vs Male | OR (≥ 20% weight loss) 2.51 | P < 0.001 |
Predictors of categorical weight loss: female sex · week 68
- Female sex was the only factor consistently associated with categorical weight loss
Safety
Adverse events
- Nausea/vomiting
- 37.3%
- Constipation
- 15.6%
- No new safety signals observed
Original publication
Real‐World Evidence on Weight Loss and Safety With Semaglutide in Obesity Telehealth: A Large Retrospective Cohort Study. Obesity (Silver Spring). Published 10 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →